Automated Chemotherapy Preparation And Infusion Market Global Report 2026

The automated chemotherapy preparation and infusion market size has grown strongly in recent years. It will grow from $1.37 billion in 2025 to $1.48 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to rising global cancer incidence, increasing adoption of hospital pharmacy automation, growing demand for accurate chemotherapy dosing, expanding oncology treatment infrastructure, increasing awareness of hazardous drug handling safety.

The automated chemotherapy preparation and infusion market size is expected to see strong growth in the next few years. It will grow to $2.04 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing demand for precision oncology workflows, growing investment in automated pharmacy infrastructure, rising adoption of personalized chemotherapy treatment, expanding outpatient cancer treatment services, increasing focus on medication traceability and regulatory compliance. Major trends in the forecast period include increasing adoption of robotic chemotherapy compounding systems, growing demand for closed system drug preparation solutions, rising focus on reducing chemotherapy medication errors, expanding implementation of sterile automated pharmacy workflows, increasing emphasis on occupational safety in oncology pharmacies.

The increasing cancer incidence is anticipated to drive the growth of the automated chemotherapy preparation and infusion market in the coming years. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells throughout the body. The rising incidence of cancer is largely attributed to the aging global population, as advancing age contributes to the accumulation of genetic mutations and prolonged exposure to cancer-related risk factors, leading to a greater prevalence of cancer. Automated chemotherapy preparation and infusion systems enhance the safety and efficiency of cancer treatment by automating drug preparation and administration, reducing medication errors, limiting healthcare worker exposure to hazardous drugs, and improving oncology workflow efficiency. For instance, in July 2026, according to the World Health Organization (WHO), a Switzerland-based health agency, annual new cancer cases reached an estimated 20.6 million worldwide, with nearly 10 million deaths, and this number is expected to increase to approximately 35 million cases by 2050. Therefore, the increasing cancer incidence is contributing to the growth of the automated chemotherapy preparation and infusion market.

Leading companies operating in the automated chemotherapy preparation and infusion market are focusing on developing advanced robotic compounding systems to improve medication accuracy, enhance workflow efficiency, and reduce healthcare workers' exposure to hazardous drugs. Robotic chemotherapy compounding systems are automated solutions that prepare chemotherapy drugs with high precision and consistency. They improve dosing accuracy, enhance workflow efficiency, and reduce healthcare workers' exposure to hazardous drugs. For example, in June 2026, Korea University Ansan Hospital, a South Korea-based healthcare organization, introduced the APOTECA Chemo robotic chemotherapy compounding system in its Department of Pharmacy. The system automates the preparation of chemotherapy medications based on individual patient prescriptions, standardizes the compounding process across treatment cycles, and minimizes healthcare workers' exposure to hazardous drugs, supporting the adoption of automated chemotherapy preparation technologies.

In June 2024, Equashield, a US-based developer of the EQUASHIELD Pro automated chemotherapy compounding robot, entered into a partnership with Pharmacy Stars to improve safety standards and regulatory adherence across healthcare operations. The collaboration combined automated hazardous drug compounding robotics with digital compliance management software to optimize chemotherapy preparation processes. As a result, it improved real-time tracking, safety validation, and record-keeping capabilities, enhancing the precision and regulatory compliance of automated oncology compounding workflows. Pharmacy Stars is a US-based provider of enterprise pharmacy compliance, regulatory management, and quality assurance software.

Major companies operating in the automated chemotherapy preparation and infusion market report are Becton Dickinson and Company, Baxter International Inc., Fresenius Kabi AG, B. Braun Melsungen AG, ICU Medical Inc., Grifols S.A., Terumo Corporation, Omnicell Inc., Moog Inc., Nipro Corporation, Equashield LLC, Loccioni Group S.r.l., ARxIUM Inc., CODAN Medizinische Geräte GmbH, Micrel Medical Devices S.A., Yuyama Co. Ltd., Simplivia Healthcare Ltd., ACE Medical Co. Ltd., Comecer S.p.A., Fagron NV.

North America was the dominant region in the automated chemotherapy preparation and infusion market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the automated chemotherapy preparation and infusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the automated chemotherapy preparation and infusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The automated chemotherapy preparation and infusion market includes revenues earned by entities by providing services such as robotic chemotherapy compounding, automated dose verification, infusion therapy management, equipment maintenance, and software integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The automated chemotherapy preparation and infusion market also includes sales ofautomated chemotherapy compounding systems, robotic chemotherapy preparation systems, automated drug compounding robots, closed-system transfer devices (CSTDs) and automated infusion pumps. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

This product will be delivered within 3-5 business days.